Correlates of depressive symptoms in transgender women initiating HIV treatment in Argentina

Simple item page
dc.contributor.authorAristegui, Ines
dc.contributor.authorRadusky, Pablo
dc.contributor.authorZalazar, Virginia
dc.contributor.authorCardozo, Nadir
dc.contributor.authorFabian, Solange
dc.contributor.authorDuarte, Mariana
dc.contributor.authorFrola, Claudia
dc.contributor.authorCahn, Pedro
dc.contributor.authorSued, Omar
dc.date.accessioned2024-05-21T01:18:30Z
dc.date.available2024-05-21T01:18:30Z
dc.date.issued2022
dc.description.abstractObjective: To assess efficacy and safety of dolutegravir (DTG) + lamivudine (3TC) vs. DTG + tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in treatment-naive adults with HIV-1 in the prespecified 144-week secondary analyses of GEMINI-1 and GEMINI-2. Design: Identical, multicenter, phase III, randomized, non-inferiority studies (double-blind through 96 weeks). Methods: Participants with HIV-1 RNA ≤500 000 copies/ml and no major viral resistance mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, or protease inhibitors were randomized 1:1 to once-daily DTG + 3TC or DTG + TDF/FTC. Results: At week 144, DTG + 3TC (N = 716) was noninferior to DTG + TDF/FTC (N = 717) in proportion of participants achieving HIV-1 RNA <50 copies/ml (Snapshot algorithm) in the pooled analysis (82% vs. 84%, respectively; adjusted treatment difference [95% confidence interval (CI)], −1.8% [−5.8, 2.1]), GEMINI-1 (−3.6% [−9.4, 2.1]), and GEMINI-2 (0.0% [−5.3, 5.3]). Twelve DTG + 3TC participants and nine DTG + TDF/FTC participants met protocol-defined confirmed virologic withdrawal (CVW) criteria; none developed treatment-emergent resistance. One DTG + 3TC participant who did not meet CVW criteria developed M184V at week 132 and R263R/K at week 144, conferring a 1.8-fold change in susceptibility to DTG; non-adherence to therapy was reported. Significantly fewer drug-related adverse events occurred with DTG + 3TC vs. DTG + TDF/FTC (20% vs. 27%; relative risk [95% CI], 0.76 [0.63–0.92]). Renal and bone biomarker changes favored DTG + 3TC. Conclusions: Three-year durable efficacy, long-term tolerability, and high barrier to resistance support first-line use of DTG + 3TC for HIV-1 treatment (see Supplemental Digital Content 1, https://links.lww.com/QAD/C297; video abstract).
dc.identifier.citationCahn, Pedroa; Sierra Madero, Juanb; Arribas, José R.c; Antinori, Andread; Ortiz, Robertoe; Clarke, Amanda E.f; Hung, Chien-Chingg; Rockstroh, Jürgen K.h; Girard, Pierre-Mariei; Sievers, Jörgj; Man, Choy Y.k; Urbaityte, Rimgailel; Brandon, Daisy J.l; Underwood, Markk; Pappa, Keith A.k; Curtis, Lloydl; Smith, Kimberly Y.k; Gartland, Martink; Aboud, Michaelj; van Wyk, Jeanj; Wynne, Briank. Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy – naive adults with HIV-1 infection. AIDS 36(1):p 39-48, January 1, 2022. | DOI: 10.1097/QAD.0000000000003070
dc.identifier.otherDOI: 10.1097/QAD.0000000000003070
dc.identifier.urihttps://repositorio.huesped.org.ar/handle/123456789/997
dc.language.isoen
dc.publisherWolters Kluwer Health
dc.relation.ispartofseriesAIDS; 36(1)
dc.subjectdolutegravir
dc.subjectintegrase strand transfer inhibitor
dc.subjectnucleoside reverse transcriptase inhibitor
dc.subjecttreatment-naive
dc.subjecttwo-drug regimen
dc.titleCorrelates of depressive symptoms in transgender women initiating HIV treatment in Argentina
dc.typeArticle

Files

License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed to upon submission
Description:
Download

Collections

Articulos científicos